Clinical Trials Logo

Clinical Trial Summary

This is a double-blind, randomized, placebo controlled, single ascending dose (SAD) study to investigate the safety, tolerability, PK and PD of the SC administration of HM15136 in healthy subjects. The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15136 or placebo in a ratio of 6:2 (6 active, 2 placebo).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04032782
Study type Interventional
Source Hanmi Pharmaceutical Company Limited
Contact
Status Completed
Phase Phase 1
Start date October 2, 2018
Completion date August 29, 2019

See also
  Status Clinical Trial Phase
Completed NCT04076293 - Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects Phase 1
Recruiting NCT05563961 - A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers N/A
Completed NCT02566733 - Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass Phase 4
Recruiting NCT06024421 - Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers Phase 1
Completed NCT02641340 - Fentanyl Sublingual Spray in Opioid Naive Participants Phase 1
Completed NCT01575587 - A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men Phase 1
Completed NCT00359541 - Voriconazole Blood Levels and Toxicity N/A